Table 4.
Variable, n (%) | Placebo (n = 13) | Teduglutide 4 mg (n = 23) |
---|---|---|
Treatment-emergent AEs |
9 (69) |
14 (61) |
Abdominal distention |
2 (15) |
8 (35) |
Constipation |
2 (15) |
5 (22) |
Headache |
2 (15) |
5 (22) |
Abdominal pain |
1 (8) |
5 (22) |
Nausea |
0 |
5 (22) |
Dyspepsia |
0 |
2 (9) |
Eructation |
0 |
2 (9) |
Extremity pain | 0 | 2 (9) |
AE = adverse event.